You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ERASCA INC

Erasca Inc XNAS: ERAS

Erasca Inc Live Share Price Today, Share Analysis and Chart

Download real time

1.16 -0.01 (-0.85%)

66.38% Fall from 52W High

952.5K XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Erasca Inc Key Metrics

Select

Market Capitalization

Below industry Median
328.6

PE TTM

Negative PE TTM
-2

PEG TTM

Below industry Median
0.1

Price to Book

Below industry Median
0.8

Institutional holding current Qtr %

Below industry Median
75.2

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-8.5

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-29.3

Piotroski Score

Below industry Median
1

Rel Perf vs Sector quarter%

-36.3

ROE Annual %

Negative ROE Annual %
-43.7

RoA Annual %

Negative RoA Annual %
-36
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
11.8 / 100
Momentum Score
Technically Bearish
26.6 / 100
Analyst Price Target
No estimates available

7

S

13

W

0

O

3

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Erasca Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Erasca Inc Stock Analysis

Erasca Inc stock analysis with key metrics, changes, and trends.

Erasca Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$161.65 M29.28%negative

Annual Net Profit fell 29.28% in the last year to $161.65 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio-2.03-negative

Price to Earning Ratio is -2.03, which is negative.

Stock Price$1.16-35.2%negative

Stock Price fell 35.2% and underperformed its sector by 42.53% in the past year.

Quarterly Net profit$32.23 M8.52%negative

Quarterly Net profit fell 8.52% YoY to $32.23 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio0.12-positive

Debt to Equity Ratio of 0.12 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-43.68 %-43.68%negative

Return on Equity(ROE) for the last financial year was -43.68%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding23.41 %-1.08%negative

Mutual Fund Holding decreased by 1.08% in the last quarter to 23.41.

Institutional Holding75.21 %-0.01%negative

Institutional Holding decreased by 0.01% in the last quarter to 75.21.

VIEW LESS


Loading data..

Erasca Inc - Company Profile

What does Erasca Inc do?

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Erasca Inc Management structure

All Gross Remunerations are in USD
Dr. Jonathan E. Lim,M.D.
Chairman of the Board and Chief Executive Officer
5.41 M
2023
Gross Remuneration
Year
Dr. David M. Chacko, M.D.
Chief Financial Officer, Principal Accounting Officer and Chief Business Officer
2.43 M
2023
Gross Remuneration
Year
Mr. Ebun S. Garner
General Counsel and Corporate Secretary
2.02 M
2023
Gross Remuneration
Year
Dr. Shannon R. Morris, M.D.,PhD
Chief Medical Officer
-
2023
Gross Remuneration
Year
Dr. Wei Lin
Chief Medical Officer
-
2023
Gross Remuneration
Year

Erasca Inc Board of directors

All Gross Remunerations are in USD
Dr. Michael D. Varney, PhD
Director
199.05 K
2023
Gross Remuneration
Year
Dr. James A. Bristol, PhD
Lead Independent Director
180.08 K
2023
Gross Remuneration
Year
Mr. Alexander W. Casdin
Independent Director
167.54 K
2023
Gross Remuneration
Year
Dr. Valerie Harding Start, PhD
Independent Director
165.54 K
2023
Gross Remuneration
Year
Dr. Julie Hambleton, M.D.
Independent Director
165.04 K
2023
Gross Remuneration
Year
Ms. Jean I. Liu
Independent Director
160.04 K
2023
Gross Remuneration
Year

Erasca Inc FAQ

How is Erasca Inc today?
Erasca Inc today is trading in the red, and is down by -0.85% at 1.16.
Erasca Inc is currently trading down -0.85% on an intraday basis. In the past week the stock fell -6.45%. stock has been down -37.30% in the past quarter and fell -35.20% in the past year. You can view this in the overview section.